|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT01056263 |
|
Date of registration:
|
25/01/2010 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
|
|
Scientific title:
|
Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival |
|
Date of first enrolment:
|
April 2010 |
|
Target sample size:
|
52 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01056263 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
|
Germany
|
United States
| | | | | |
|
Contacts
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Pfizer |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subjects participating in this observational study originally participated in study
A4061012 [NCT00076011] and may have also participated in study A4061008 [NCT00828919]
Exclusion Criteria:
- Subjects who withdrew from the original study A4061012 [NCT00076011] or the continuing
access study A4061008 [NCT00828919]
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Carcinoma, Renal Cell
|
|
Intervention(s)
|
|
Drug: axitinib: observational study
|
|
Primary Outcome(s)
|
|
Overall Survival (OS)
[Time Frame: Baseline until death or up to Year 5]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|